Trending...
- New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks
- Capacity Crunch for Cold Plating? Not Anymore
- Tami Goveia Enters FabOver40, Inspiring Hollywood Legacy for Breast Cancer Cause
CHICAGO, July 31, 2024 ~ As the ADLM 2024 (formerly known as the AACC Annual Scientific Meeting & Clinical Lab Expo) kicks off in Chicago, Fapon, a global leading life sciences company, is proud to showcase its innovative IVD total solutions. From July 28 to August 1, attendees will have the opportunity to witness firsthand Fapon's commitment to supporting local partners and delivering customized solutions with advanced innovations and dedicated localization services.
With over two decades of experience in the industry, Fapon has established itself as a pioneer in cutting-edge technology platforms. These include antibody discovery, protein expression, cell fermentation, and protein purification and analysis. In order to continue driving innovation in the field, Fapon has set up an R&D center in Boston focused on molecular diagnostic enzymes and circRNA, as well as an R&D center in San Francisco for next-generation sequencing (NGS) and artificial intelligence (AI). These centers are dedicated to offering innovative diagnostic solutions to the market.
More on illi News
Fapon has also established a deep-rooted presence in the US market through localized strategies that prioritize customer needs and service. With R&D and production facilities set up in the US market, along with a team of dedicated R&D scientists, sales representatives, and technical support experts, Fapon is able to leverage cutting-edge innovations in diagnostic technologies and provide prompt support to local partners backed by a robust supply chain system. Additionally, their commitment to quality is evident through their ISO 13485 and ISO 9001 certifications which guarantee reliable and consistent delivery of superior products.
At ADLM 2024, Fapon is showcasing their comprehensive range of customized IVD solutions. This includes high-performance raw materials, reagent services, and open-system platforms specifically tailored for each client's business needs. Among their new raw material products being showcased are antigens and antibodies for assays related to Alzheimer's Disease (AD), fentanyl testing kits, as well as new products for molecular diagnostics. Fapon also offers reagent solutions for qPCR/RT-qPCR, isothermal amplification, and NGS library preparation, with a focus on enzyme innovation using AI-based enzyme engineering. Their portfolio also includes high-performance raw materials for influenza testing, particularly for H5N1, and products for cardiac markers to meet the specific demands of the US market.
More on illi News
In addition to their existing CLIA analyzer platforms, Fapon has expanded their offerings with the launch of two new additions: Shine i6000 with a throughput of 600T/H and Shine i3000 with a throughput of 300T/H. These new additions provide customers with more options for throughput choices. To complement their range of analyzers, Fapon has also introduced two cutting-edge and fully automated molecular diagnostic systems - Ideal 30 for human diagnostics and Nous 30V for veterinary diagnostics. These innovative platforms are designed to accelerate product development processes and offer customized options for their valued customers.
Looking towards the future, Fapon remains committed to providing innovative IVD solutions and refining their product offerings to meet the ever-evolving needs of the US IVD market segment. With their deep-rooted presence in the US market and dedication to cutting-edge research and development, Fapon is poised to continue leading the way in delivering customized IVD solutions that meet the highest standards of quality and performance.
With over two decades of experience in the industry, Fapon has established itself as a pioneer in cutting-edge technology platforms. These include antibody discovery, protein expression, cell fermentation, and protein purification and analysis. In order to continue driving innovation in the field, Fapon has set up an R&D center in Boston focused on molecular diagnostic enzymes and circRNA, as well as an R&D center in San Francisco for next-generation sequencing (NGS) and artificial intelligence (AI). These centers are dedicated to offering innovative diagnostic solutions to the market.
More on illi News
- Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
- Digi 995 Universe expands with the Launch of Digi 995: Tile Match
- Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- Art Fair Success-See Behind The Scenes With New Photo Album
Fapon has also established a deep-rooted presence in the US market through localized strategies that prioritize customer needs and service. With R&D and production facilities set up in the US market, along with a team of dedicated R&D scientists, sales representatives, and technical support experts, Fapon is able to leverage cutting-edge innovations in diagnostic technologies and provide prompt support to local partners backed by a robust supply chain system. Additionally, their commitment to quality is evident through their ISO 13485 and ISO 9001 certifications which guarantee reliable and consistent delivery of superior products.
At ADLM 2024, Fapon is showcasing their comprehensive range of customized IVD solutions. This includes high-performance raw materials, reagent services, and open-system platforms specifically tailored for each client's business needs. Among their new raw material products being showcased are antigens and antibodies for assays related to Alzheimer's Disease (AD), fentanyl testing kits, as well as new products for molecular diagnostics. Fapon also offers reagent solutions for qPCR/RT-qPCR, isothermal amplification, and NGS library preparation, with a focus on enzyme innovation using AI-based enzyme engineering. Their portfolio also includes high-performance raw materials for influenza testing, particularly for H5N1, and products for cardiac markers to meet the specific demands of the US market.
More on illi News
- 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
- Easton & Easton, LLP Sues The Dwelling Place Anaheim and Vineyard USA for Failing to Protect Minor from Church Leaders' Sexual Abuse
- Chicago: Mayor Brandon Johnson Stands With Congressional Leaders, Meets With Residents About Ongoing ICE Raids
- Predatory Refinancing: How Desperate Homeowners Are Tricked Into Losing Their Equity
- Isringhausen Imports Announces 2025 DRIVE Grant Recipients
In addition to their existing CLIA analyzer platforms, Fapon has expanded their offerings with the launch of two new additions: Shine i6000 with a throughput of 600T/H and Shine i3000 with a throughput of 300T/H. These new additions provide customers with more options for throughput choices. To complement their range of analyzers, Fapon has also introduced two cutting-edge and fully automated molecular diagnostic systems - Ideal 30 for human diagnostics and Nous 30V for veterinary diagnostics. These innovative platforms are designed to accelerate product development processes and offer customized options for their valued customers.
Looking towards the future, Fapon remains committed to providing innovative IVD solutions and refining their product offerings to meet the ever-evolving needs of the US IVD market segment. With their deep-rooted presence in the US market and dedication to cutting-edge research and development, Fapon is poised to continue leading the way in delivering customized IVD solutions that meet the highest standards of quality and performance.
Filed Under: Business
0 Comments
Latest on illi News
- Local Businesses Host ALL HANDS PARTY for Community Involvement 11.14.25
- i2 Group Acquisitions and Investments in Innovations Deliver 40% Increase in Year-on-Year Bookings
- New Book Release: The Tree That Could Not Change
- BayWa r.e. Solar Trade and WHES Announce Distribution Partnership for the European Market: Delivering Smarter Energy Storage
- Fleet Mining Cloud Mining Platform — Latest Guide: Making Bitcoin Mining Safer and More Convenient
- Leo Choir × Confidence Apparel: From Fashion Week to the Chicago Bulls Arena
- Keebos Launches Crossbody Cases for Every iPhone 17 Model
- WOA Crypto redefines cloud Bitcoin mining, offering free access and instant profit opportunities
- Pepperdine University Malibu, California and Community Partners Recognized with 2025 ReadyCommunities Partnership National Service Award
- NBA Overachievers: OddsTrader Reveals Which Teams Will Exceed Expectations in 2025-26
- Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
- TKL Group's New Factory Commences Production, Pioneering A New Era In Global Heavy Duty Truck Parts
- Regulated Crypto Exchange TZNXG Addresses Core US Market Challenges with Compliance-First Infrastructure
- Unleash Your Inner Seduction at HandPickedSC.com's "The Hot & The Wicked Halloween Soirée"
- GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
- ZapperBox NextGen TV Gateway Receiver Now Testing Support For Secure Whole-Home Content Distribution
- Life as a Dog: P-Wave Press Brings Readers a Heartwarming Memoir of Love, Laughter and Companionship
- NOYA Launches Premium, Design-Forward Training Gear That Belongs at the Center of Your Space
- Research Defense Examines Violence, Illiteracy, Non-Active Fathers, and Low Self-Esteem Among Males